See What HealthDay Can Do For You
Contact Us

Tissue Factor Pathway Inhibitor Levels Up in Women With MI

Increased tissue factor pathway inhibitor activity, activated protein C-sensitivity linked to MI

THURSDAY, Sept. 15 (HealthDay News) -- Young women with myocardial infarction (MI) have higher tissue factor pathway inhibitor (TFPI) levels in comparison to those without MI, with increased TFPI activities and activated protein C (APC)-sensitivity correlating with MI, according to a study published online Sept. 5 in the Journal of Thrombosis and Haemostasis.

Kristien Winckers, M.D., from the Maastricht University Medical Center in the Netherlands, and colleagues investigated the influence of the TFPI/protein S anticoagulant system on the risk of MI in women younger than 50 years. A total of 205 women with MI and 638 controls were enrolled, and underwent enzyme-linked immunosorbent assay to quantify TFPI and protein S. Thrombin generation tests were used to determine TFPI/protein S activity and APC-sensitivity ratio.

The investigators found that women with MI had elevated levels of TFPI (135.9 ± 40 percent versus 124.2 ± 41 percent) resulting in increased TFPI/protein S activities and increased APC-sensitivity. Increased TFPI activity was correlated with MI (adjusted odds ratio [OR] quartile one versus quartile four, 2.1). APC-sensitivity was also correlated with MI (adjusted OR quartile one versus quartile four, 1.7; 95 percent confidence interval, 0.9 to 3.2).

"Women with MI have increased TFPI levels compared with controls. Consequently, the TFPI/protein S activity and APC-sensitivity are increased in women with MI," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.